Cargando…

Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer

The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 6...

Descripción completa

Detalles Bibliográficos
Autores principales: CHEN, WEICAI, HE, JINSONG, SONG, SHUFEN, WANG, MIN, WU, HUISHENG, WANG, XIANMING
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356353/
https://www.ncbi.nlm.nih.gov/pubmed/25789069
http://dx.doi.org/10.3892/ol.2015.2912
_version_ 1782360985189744640
author CHEN, WEICAI
HE, JINSONG
SONG, SHUFEN
WANG, MIN
WU, HUISHENG
WANG, XIANMING
author_facet CHEN, WEICAI
HE, JINSONG
SONG, SHUFEN
WANG, MIN
WU, HUISHENG
WANG, XIANMING
author_sort CHEN, WEICAI
collection PubMed
description The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 64 cases of HER-2-overexpressing breast cancer patients was divided into two groups according to their treatment preferences: The TCH group, consisting of 39 patients, and the TEC group, consisting of 25 patients. The neoadjuvant chemotherapy was continued for six cycles prior to comparison of the treatment efficacy. The TCG and TEC groups exhibited an overall response rate of 94.9 and 72.0% (37/39 and 18/25 cases; P<0.05), respectively, and a pathological complete response (pCR; defined as the presence of no invasive or in situ residual tumors in the breast) rate of 69.2 and 32.0% (27/39 and 8/25 cases; P<0.05), respectively. Furthermore, no significant differences were identified between the two groups of patients in terms of adverse reactions, such as cardiac dysfunction, bone marrow suppression and liver function impairment. In the present study, the treatment of HER-2-overexpressing breast cancer patients with TCH neoadjuvant chemotherapy demonstrated more favorable efficacy and a higher pCR rate when compared with the TEC-treated group.
format Online
Article
Text
id pubmed-4356353
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-43563532015-03-18 Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer CHEN, WEICAI HE, JINSONG SONG, SHUFEN WANG, MIN WU, HUISHENG WANG, XIANMING Oncol Lett Articles The aim of the present study was to observe the efficacy of neoadjuvant trastuzumab combined with docetaxel and carboplatin (TCH), and docetaxel, epirubicin and cyclophosphamide (TEC) chemotherapy in human epidermal growth factor receptor-2 (HER-2)-overexpressing breast cancer. The total cohort of 64 cases of HER-2-overexpressing breast cancer patients was divided into two groups according to their treatment preferences: The TCH group, consisting of 39 patients, and the TEC group, consisting of 25 patients. The neoadjuvant chemotherapy was continued for six cycles prior to comparison of the treatment efficacy. The TCG and TEC groups exhibited an overall response rate of 94.9 and 72.0% (37/39 and 18/25 cases; P<0.05), respectively, and a pathological complete response (pCR; defined as the presence of no invasive or in situ residual tumors in the breast) rate of 69.2 and 32.0% (27/39 and 8/25 cases; P<0.05), respectively. Furthermore, no significant differences were identified between the two groups of patients in terms of adverse reactions, such as cardiac dysfunction, bone marrow suppression and liver function impairment. In the present study, the treatment of HER-2-overexpressing breast cancer patients with TCH neoadjuvant chemotherapy demonstrated more favorable efficacy and a higher pCR rate when compared with the TEC-treated group. D.A. Spandidos 2015-04 2015-01-28 /pmc/articles/PMC4356353/ /pubmed/25789069 http://dx.doi.org/10.3892/ol.2015.2912 Text en Copyright © 2015, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Articles
CHEN, WEICAI
HE, JINSONG
SONG, SHUFEN
WANG, MIN
WU, HUISHENG
WANG, XIANMING
Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
title Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
title_full Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
title_fullStr Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
title_full_unstemmed Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
title_short Efficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer
title_sort efficacy of tch/tec neoadjuvant chemotherapy for the treatment of her-2-overexpressing breast cancer
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356353/
https://www.ncbi.nlm.nih.gov/pubmed/25789069
http://dx.doi.org/10.3892/ol.2015.2912
work_keys_str_mv AT chenweicai efficacyoftchtecneoadjuvantchemotherapyforthetreatmentofher2overexpressingbreastcancer
AT hejinsong efficacyoftchtecneoadjuvantchemotherapyforthetreatmentofher2overexpressingbreastcancer
AT songshufen efficacyoftchtecneoadjuvantchemotherapyforthetreatmentofher2overexpressingbreastcancer
AT wangmin efficacyoftchtecneoadjuvantchemotherapyforthetreatmentofher2overexpressingbreastcancer
AT wuhuisheng efficacyoftchtecneoadjuvantchemotherapyforthetreatmentofher2overexpressingbreastcancer
AT wangxianming efficacyoftchtecneoadjuvantchemotherapyforthetreatmentofher2overexpressingbreastcancer